{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T22:31:33Z","timestamp":1779316293363,"version":"3.51.4"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.ejca.2021.01.046","type":"journal-article","created":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T20:22:41Z","timestamp":1614198161000},"page":"316-327","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"special_numbering":"C","title":["SARS-CoV-2 vaccines for cancer patients: a call to action"],"prefix":"10.1016","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0359-0267","authenticated-orcid":false,"given":"Chiara","family":"Corti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1869-0607","authenticated-orcid":false,"given":"Edoardo","family":"Crimini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8686-0228","authenticated-orcid":false,"given":"Paolo","family":"Tarantino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"Pravettoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander M.M.","family":"Eggermont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzette","family":"Delaloge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1781-2518","authenticated-orcid":false,"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2021.01.046_bib1","unstructured":"WHO: Coronavirus disease (COVID-19) pandemic. Numbers at a glance. https:\/\/bit.ly\/3ckwmCD. [Accessed 22 January 2021]."},{"issue":"13","key":"10.1016\/j.ejca.2021.01.046_bib2","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1001\/jama.2020.17023","article-title":"Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis","volume":"324","author":"Sterne","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2021.01.046_bib3","doi-asserted-by":"crossref","first-page":"m2980","DOI":"10.1136\/bmj.m2980","article-title":"Drug treatments for covid-19: living systematic review and network meta-analysis","volume":"370","author":"Siemieniuk","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.ejca.2021.01.046_bib4","article-title":"Repurposed antiviral drugs for covid-19 \u2013 interim WHO solidarity trial results","author":"Pan","year":"2020","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ejca.2021.01.046_bib5","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of covid-19 \u2013 final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.01.046_bib6","first-page":"CD013600","article-title":"Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review","volume":"7","author":"Piechotta","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ejca.2021.01.046_bib7","unstructured":"The RECOVERY trial chief investigators. \"RECOVERY trial closes recruitment to convalescent plasma treatment for patients hospitalised with COVID-19\". 14th January 2021. https:\/\/bit.ly\/3sveWsu."},{"key":"10.1016\/j.ejca.2021.01.046_bib8","unstructured":"Coronavirus (COVID-19) update: FDA authorizes monoclonal antibody for treatment of COVID-19. https:\/\/bit.ly\/2McxI7e. [Accessed 22 January 2021]."},{"key":"10.1016\/j.ejca.2021.01.046_bib9","unstructured":"Coronavirus (COVID-19) update: FDA authorizes monoclonal antibodies for treatment of COVID-19. https:\/\/bit.ly\/3a1l5Eu. [Accessed 22 January 2021]."},{"issue":"3","key":"10.1016\/j.ejca.2021.01.046_bib10","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa2029849","article-title":"SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with covid-19","volume":"384","author":"Chen","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.01.046_bib11","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.3389\/fpsyg.2020.567230","article-title":"Patients living with breast cancer during the coronavirus pandemic: the role of family resilience, coping flexibility, and locus of control on affective responses","volume":"11","author":"Brivio","year":"2021","journal-title":"Front Psychol"},{"key":"10.1016\/j.ejca.2021.01.046_bib12","first-page":"1","article-title":"From individual to social trauma: sources of everyday trauma in Italy, the US and UK during the covid-19 pandemic","author":"Masiero","year":"2020","journal-title":"J Trauma Dissociation"},{"issue":"10241","key":"10.1016\/j.ejca.2021.01.046_bib13","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(20)31187-9","article-title":"Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study","volume":"395","author":"Kuderer","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ejca.2021.01.046_bib14","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"7798","key":"10.1016\/j.ejca.2021.01.046_bib15","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new coronavirus associated with human respiratory disease in China","volume":"579","author":"Wu","year":"2020","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.ejca.2021.01.046_bib16","doi-asserted-by":"crossref","first-page":"362","DOI":"10.7326\/M20-3012","article-title":"Prevalence of asymptomatic SARS-CoV-2 infection : a narrative review","volume":"173","author":"Oran","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejca.2021.01.046_bib17","doi-asserted-by":"crossref","first-page":"m1985","DOI":"10.1136\/bmj.m1985","article-title":"Features of 20\u2009133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study","volume":"369","author":"Docherty","year":"2020","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.ejca.2021.01.046_bib18","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/s41467-020-15562-9","article-title":"Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV","volume":"11","author":"Ou","year":"2020","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.ejca.2021.01.046_bib19","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","article-title":"Targets of T Cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals","volume":"181","author":"Grifoni","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ejca.2021.01.046_bib20","unstructured":"WHO draft landscape of Covid-19 candidate vaccines. https:\/\/bit.ly\/2WPuad6. [Accessed 22 January 2021]."},{"key":"10.1016\/j.ejca.2021.01.046_bib21","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","author":"Baden","year":"2020","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.ejca.2021.01.046_bib22","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"issue":"7821","key":"10.1016\/j.ejca.2021.01.046_bib23","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","article-title":"Factors associated with COVID-19-related death using OpenSAFELY","volume":"584","author":"Williamson","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2021.01.046_bib24","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ejca.2020.08.017","article-title":"High mortality among hospital-acquired COVID-19 infection in patients with cancer: a multicentre observational cohort study","volume":"139","author":"Elkrief","year":"2020","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2021.01.046_bib25","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejca.2020.09.035","article-title":"Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: a French nationwide cohort study (GCO-002 CACOVID-19)","volume":"141","author":"Li\u00e8vre","year":"2020","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2021.01.046_bib26","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejca.2020.09.027","article-title":"Dutch oncology COVID-19 consortium: outcome of COVID-19 in patients with cancer in a nationwide cohort study","volume":"141","author":"de Joode","year":"2020","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2021.01.046_bib27","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ejca.2020.08.011","article-title":"Mortality in patients with cancer and coronavirus disease 2019: a systematic review and pooled analysis of 52 studies","volume":"139","author":"Saini","year":"2020","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2021.01.046_bib28","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejca.2020.09.028","article-title":"A systematic review and meta-analysis: the effect of active cancer treatment on severity of COVID-19","volume":"141","author":"Yeked\u00fcz","year":"2020","journal-title":"Eur J Canc"},{"issue":"7","key":"10.1016\/j.ejca.2021.01.046_bib29","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S1470-2045(20)30314-4","article-title":"COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study","volume":"21","author":"Garassino","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.01.046_bib30","unstructured":"Garassino MC, Giesen N, Grivas P, Jordan K, Lucibello F, Mir O, et\u00a0al.: ESMO Statements for Vaccination against COVID-19 in patients with cancer. https:\/\/bit.ly\/3swNx9G. [Accessed 16 January 2020]."},{"issue":"2","key":"10.1016\/j.ejca.2021.01.046_bib31","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000759","article-title":"Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: young oncologists' perspective","volume":"5","author":"Lambertini","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2021.01.046_bib32","doi-asserted-by":"crossref","first-page":"914","DOI":"10.3332\/ecancer.2019.914","article-title":"The role of emotions in cancer patients' decision-making","volume":"13","author":"Mazzocco","year":"2019","journal-title":"Ecancermedicalscience"},{"key":"10.1016\/j.ejca.2021.01.046_bib33","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1186\/2193-1801-3-392","article-title":"PTSD symptoms as a consequence of breast cancer diagnosis: clinical implications","volume":"3","author":"Arnaboldi","year":"2014","journal-title":"SpringerPlus"},{"key":"10.1016\/j.ejca.2021.01.046_bib34","article-title":"Association of the COVID-19 outbreak with patient willingness to enroll in cancer clinical trials","author":"Fleury","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2021.01.046_bib35","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2020.03.023","article-title":"Conducting phase 1 cancer clinical trials during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related disease pandemic","volume":"132","author":"Tarantino","year":"2020","journal-title":"Eur J Canc"},{"issue":"supplement 4","key":"10.1016\/j.ejca.2021.01.046_bib36","doi-asserted-by":"crossref","first-page":"S1206","DOI":"10.1016\/j.annonc.2020.08.2318","article-title":"Anti-SARS-CoV-2 antibody response in patients with cancer and oncology healthcare workers: a multicenter, prospective study","volume":"31","author":"Marra","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.01.046_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2020.12.019","article-title":"Commentary: SARS-CoV-2 vaccines and cancer patients","author":"Corti","year":"2021","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2021.01.046_bib38","first-page":"398","article-title":"The importance of immunization in cancer prevention, treatment, and survivorship","volume":"67","author":"Ward","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"10.1016\/j.ejca.2021.01.046_bib39","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.annonc.2020.03.290","article-title":"Immunogenicity and safety of influenza vaccination in cancer patients receiving checkpoint inhibitors targeting PD-1 or PD-L1","volume":"31","author":"Bayle","year":"2020","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2021.01.046_bib40","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1093\/annonc\/mdr141","article-title":"Immunogenicity and safety of the influenza A H1N1v 2009 vaccine in cancer patients treated with cytotoxic chemotherapy and\/or targeted therapy: the VACANCE study","volume":"23","author":"Rousseau","year":"2012","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2021.01.046_bib41","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1093\/annonc\/mdy117","article-title":"Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors-guideline of the infectious diseases working party (AGIHO) of the German Society for hematology and medical oncology (DGHO)","volume":"29","author":"Rieger","year":"2018","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2021.01.046_bib42","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1093\/cid\/cit684","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ejca.2021.01.046_bib43","unstructured":"Preliminary Recommendations of the NCCN COVID-19 vaccination advisory committee. Version 1.0 1\/22\/2021. https:\/\/bit.ly\/3qN6uTD. [Accessed 22 January 2021]."},{"issue":"5","key":"10.1016\/j.ejca.2021.01.046_bib44","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.mayocp.2020.03.021","article-title":"Empowering communication in emergency contexts: reflections from the Italian coronavirus outbreak","volume":"95","author":"Brivio","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ejca.2021.01.046_bib45","unstructured":"WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination, 14 September 2020. World Health Organization. https:\/\/bit.ly\/35NPC7m. License: CC BY-NC-SA 3.0 IGO."}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921000824?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921000824?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:31:56Z","timestamp":1760733116000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921000824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":45,"alternative-id":["S0959804921000824"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.01.046","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SARS-CoV-2 vaccines for cancer patients: a call to action","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.01.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}